U.S. Metals and Mining Stock News

NasdaqGS:TOWN
NasdaqGS:TOWNBanks

TowneBank Integration Progress With Village And Dogwood Reshapes Growth Outlook

TowneBank (NasdaqGS:TOWN) has completed most of the integration work related to Village. The company is preparing to finalize its partnership and integration plans with Dogwood. These organizational changes mark a new phase in TowneBank’s combination and partnership activity. TowneBank operates as a community focused financial institution, so how it brings acquired or partnered businesses onto a common platform can matter for service quality, internal efficiency, and risk controls. With the...
OTCPK:UTGN
OTCPK:UTGNInsurance

United Guardian (OTCPK:UTGN) Q4 Loss And Margin Compression Challenge Bullish Narratives

United Guardian (OTCPK:UTGN) has wrapped up FY 2025 with a mixed set of numbers, as Q4 revenue came in at a slight loss of US$0.3 million and net income swung to a loss of US$4.2 million, against a backdrop where trailing 12 month revenue sits at US$42.3 million and net income at US$17.1 million. Over recent quarters the company has seen revenue move from US$16.2 million and EPS of US$2.33 in Q4 2024 to US$21.9 million and EPS of US$4.05 in Q1 2025, before settling at US$17.3 million and EPS...
NYSE:MPLX
NYSE:MPLXOil and Gas

Is MPLX (MPLX) Still Attractive After Strong Multi Year Price Gains?

If you are wondering whether MPLX at around US$58.96 is still offering value or starting to look fully priced, you are in the right place. The unit price has delivered returns of 1.2% over the last 7 days, 0.1% over 30 days, 9.4% year to date, 18.8% over 1 year and very large gains over 3 and 5 years, which naturally raises questions about what is already reflected in the current valuation. Recent news coverage has focused on MPLX's position within the US energy infrastructure space and how...
NYSE:CMC
NYSE:CMCMetals and Mining

Commercial Metals (CMC) Margin Rebound Challenges Bearish Earnings Narratives

Commercial Metals (CMC) has just turned in its Q2 2026 scorecard, with Q1 2026 revenue of US$2.1 billion and net income of US$177.3 million translating into EPS of US$1.60, while trailing twelve month figures show revenue of US$8.0 billion, net income of US$437.7 million and EPS of US$3.90. Investors have seen revenue move from US$1.8 billion in Q2 2025 to US$2.1 billion in Q1 2026, as EPS swung from US$0.22 to US$1.60 over the same stretch. This sets up a quarter where higher earnings are...
NYSE:MWA
NYSE:MWAMachinery

Mueller Water Director Purchase Underscores Confidence In Free Cash Flow Story

Mueller Water Products director Gregg C. Sengstack recently increased his personal stake through an open-market share purchase. The insider transaction signals clear internal commitment to the company’s direction and outlook. The move comes as investors are watching insider activity at NYSE:MWA for additional clues about management’s confidence. Mueller Water Products, ticker NYSE:MWA, is drawing fresh attention after this insider purchase, with the stock most recently closing at $27.8. The...
NasdaqGS:PGEN
NasdaqGS:PGENBiotechs

Precigen (PGEN) Quarterly Loss Swings Challenge Bullish Growth Narrative After FY 2025 Results

Precigen (PGEN) has just closed out FY 2025 with fourth quarter revenue of US$4.6 million, a basic EPS loss of US$0.07, and net income loss of US$23.5 million. Over the past year, the company has seen revenue move from US$1.2 million in Q4 2024 to US$4.6 million in Q4 2025. Trailing twelve month basic EPS sits at a loss of US$1.37 and net income loss over the same period totals US$429.6 million, which keeps the spotlight firmly on how quickly margins can improve from here. See our full...
NasdaqGS:OLED
NasdaqGS:OLEDSemiconductor

Universal Display Uses ICDT 2026 Stage To Reinforce PHOLED Investment Story

Universal Display (NasdaqGS:OLED) is set to be in the spotlight at ICDT 2026 as a technical sponsor of the conference. The company is highlighting new OLED materials technology, with a focus on advances in emissive layer design. A principal technologist from Universal Display is giving an invited talk on PHOLED materials, underscoring their role in next generation display architectures. Universal Display, known for its OLED materials and licensing business, is positioned within long running...
OTCPK:MGTE
OTCPK:MGTEDiversified Financial

Marblegate Capital (OTCPK:MGTE) Revenue Decline Of 35.8% Tests Bullish Recovery Narratives

Marblegate Capital (OTCPK:MGTE) has just posted its FY 2025 numbers, reporting Q3 revenue of US$12.0 million and a basic EPS loss of US$0.02. This is set against a trailing 12 month revenue base of US$10.3 million and a basic EPS loss of US$0.91 that reflects the broader year. Over recent quarters, the company’s revenue has moved from US$5.1 million in Q2 2024 to US$5.4 million in Q3 2024 and then to US$4.6 million, US$9.7 million and US$12.0 million in Q1, Q2 and Q3 2025 respectively. EPS...
NYSE:XYF
NYSE:XYFConsumer Finance

X Financial (NYSE:XYF) One Off CN¥3.2b Loss Tests Bullish Earnings Narrative

X Financial (NYSE:XYF) has put solid numbers on the board for FY 2025 so far, with Q3 revenue of CN¥1,960.9 million and basic EPS of CN¥10.58, while trailing 12 month figures sit at CN¥7.9 billion of revenue and basic EPS of CN¥42.07, underpinned by net income of CN¥1,793.0 million. Over recent reporting periods the company has seen revenue move from CN¥1,372.6 million in Q2 2024 to CN¥2,273.1 million in Q2 2025. Quarterly basic EPS shifted from CN¥8.48 to CN¥12.59, setting up a results...
NYSE:KRMN
NYSE:KRMNAerospace & Defense

Karman Holdings (KRMN) Q4 Revenue Growth Tests Bullish Margin Expansion Narrative

Karman Holdings (KRMN) has just wrapped up FY 2025 with fourth quarter revenue of US$134.5 million and net income of US$7.7 million, translating to basic EPS of US$0.06. Over the past six quarters, the company has seen revenue move from US$86.0 million in Q3 2024 to US$134.5 million in Q4 2025, while quarterly EPS shifted from US$0.03 to roughly US$0.06, against a backdrop of trailing twelve month EPS of US$0.13 and net income of US$17.4 million. With net profit margins sitting at 3.7% and...
NasdaqCM:DERM
NasdaqCM:DERMPharmaceuticals

Journey Medical (DERM) Losses Narrow In Q4 EPS Result Tests Bullish Profitability Narrative

Journey Medical (DERM) closed FY 2025 with Q4 revenue of US$16.1 million and a basic EPS loss of US$0.05, while trailing twelve month figures show revenue of US$61.9 million and a basic EPS loss of US$0.47. Over recent quarters, revenue has ranged from US$13.1 million in Q1 2025 to US$17.6 million in Q3 2025, with basic EPS moving between a loss of US$0.18 and a loss of US$0.05. This sets up a story in which top line scale is building while margins remain under pressure. See our full analysis...
NasdaqCM:FXNC
NasdaqCM:FXNCBanks

First National (FXNC) Net Interest Margin Strengthens Bullish Narratives In FY 2025 Earnings

First National (FXNC) has reported FY 2025 results with fourth quarter revenue of US$23.0 million and EPS of US$0.61, capping a trailing twelve month revenue line of US$87.0 million and EPS of US$1.97 that reflects 154.1% earnings growth over the past year. Over recent periods, revenue has moved from US$13.3 million in Q3 2024 to US$17.1 million in Q4 2024 and then to US$23.0 million in Q4 2025. Quarterly EPS shifted from a loss of US$0.10 in Q4 2024 to US$0.61 in Q4 2025, highlighting a...
OTCPK:AMRQ.F
OTCPK:AMRQ.FMetals and Mining

Amaroq (OTCPK:AMRQ.F) Q3 Revenue Breakout Tests Bullish Growth Narrative Against Ongoing Losses

Amaroq Q3 2025 earnings snapshot Amaroq (OTCPK:AMRQ.F) has just reported Q3 2025 results with revenue of C$12.8 million and a basic EPS loss of C$0.0117, alongside trailing twelve month revenue of C$16.3 million and a basic EPS loss of C$0.0511. Over recent quarters the company has seen revenue move from C$0 in Q3 2024 to C$3.4 million in Q2 2025 and then to C$12.8 million in Q3 2025, while quarterly basic EPS has ranged between a loss of C$0.0428 and a loss of C$0.0111 across the same...
NasdaqGM:KALV
NasdaqGM:KALVBiotechs

KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative

KalVista Pharmaceuticals (KALV) closed FY 2025 with fourth quarter revenue of US$59.9 million and a basic EPS loss of US$0.10, alongside net income excluding extra items of a US$5.4 million loss. This provides a clear snapshot of a business still in investment mode. The company has seen quarterly revenue shift from US$13.7 million in FY 2025 Q3 to US$59.9 million in FY 2025 Q4, while basic EPS moved from a US$0.92 loss to a US$0.10 loss over the same period, highlighting a set of results...
NYSE:FUL
NYSE:FULChemicals

H.B. Fuller (FUL) Q1 2026 Margin Improvement Tests Bullish Profitability Narrative

H.B. Fuller (FUL) opened Q1 2026 with total revenue of US$770.8 million and basic EPS of US$0.38, against a backdrop of trailing twelve month revenue of US$3.5 billion and basic EPS of US$2.93 that has been supported by 41.8% earnings growth over the last year. Over recent quarters, the company has seen quarterly revenue move from US$788.7 million in Q1 2025 to US$894.8 million in Q4 2025 before landing at US$770.8 million in Q1 2026. Basic EPS over that span ranged from US$0.24 to US$1.23,...
NYSE:GME
NYSE:GMESpecialty Retail

GameStop (GME) Net Margin Jump To 11.5% Tests Bullish Profitability Narratives

GameStop (GME) has just wrapped up FY 2026 with fourth quarter revenue of US$1,104.3 million and basic EPS of US$0.29 on net income of US$127.9 million, capping a twelve month period where trailing revenue was US$3,629.9 million and EPS reached US$0.93 on net income of US$418.4 million. Across the year, quarterly revenue moved between US$732.4 million and US$1,104.3 million while basic EPS ranged from US$0.10 to US$0.38. This provides a clearer view of how the top line and per share earnings...
NasdaqGS:CZR
NasdaqGS:CZRHospitality

Caesars Bets On Vanderpump Hotel To Expand Non Gaming Appeal

Caesars Entertainment (NasdaqGS:CZR) is converting The Cromwell on the Las Vegas Strip into The Vanderpump Hotel. The new boutique property is positioned around Lisa Vanderpump's hospitality brand and design concepts. The launch introduces a non gaming focused draw within Caesars' broader Las Vegas portfolio. For Caesars Entertainment, the move fits with a broader shift in Las Vegas toward high profile branded hospitality concepts, where food, beverage and design carry as much weight as...
NYSE:JBS
NYSE:JBSFood

JBS (NYSE:JBS) Margin Stagnation Tests Bullish Earnings Rebound Narrative

JBS (NYSE:JBS) FY 2025 earnings snapshot JBS (NYSE:JBS) has reported its FY 2025 numbers with Q4 revenue of US$23.1 billion and basic EPS of US$0.43, alongside trailing twelve month EPS of US$1.89 on revenue of US$86.2 billion, setting the stage for a closer look at how the year stacked up. Over recent periods the company has seen quarterly revenue move from US$22.6 billion in Q3 2025 to US$23.1 billion in Q4 2025, while quarterly basic EPS shifted from US$0.52 to US$0.43 and annual earnings...
NYSE:SFL
NYSE:SFLOil and Gas

The Bull Case For SFL (SFL) Could Change Following New US$170 Million Hercules Rig Contract

SFL Corporation announced that it has secured a drilling agreement in Canada for its semi-submersible rig Hercules, an estimated US$170 million contract for a minimum of 400 days, with Odfjell Drilling to operate the unit after preparation in Norway. This contract meaningfully enhances visibility on future rig utilization and cash inflows from Hercules, a previously idle asset highlighted as a risk in the earlier investment narrative. We’ll examine how this new US$170 million Hercules...
NYSE:DHT
NYSE:DHTOil and Gas

DHT Shelf Filing Adds Capital Flexibility And Potential Valuation Impact

DHT Holdings (NYSE:DHT) has filed a universal shelf registration statement covering multiple classes of securities. The filing allows the company to issue common stock, preferred stock, warrants, and rights over time as needed. This structure is designed to give DHT Holdings more flexibility in how and when it raises capital. DHT Holdings operates in the tanker shipping sector, a part of the energy supply chain that often responds directly to global trade flows and oil transport demand. A...
NasdaqCM:ONDS
NasdaqCM:ONDSCommunications

Ondas Moves Toward Defense Prime Role With Mistral Deal And Palantir AI

Ondas Holdings (NasdaqCM:ONDS) agreed to acquire U.S. defense prime contractor Mistral Inc. in a cash and stock deal valued at about $175m. The company reported a $15.8m demining order linked to this transition into prime contractor roles within U.S. defense programs. Ondas expanded its partnership with Palantir to support AI powered, multi domain intelligence and ISR infrastructure across its platforms. For investors following defense technology, Ondas has mostly been known for...
NYSE:GMED
NYSE:GMEDMedical Equipment

Globus Medical Director Exit Puts Governance And M&A Oversight In Focus

Globus Medical (NYSE:GMED) has announced that board director John A. DeFord is stepping down from its Board of Directors with immediate effect. DeFord served on the board during key corporate events, including the NuVasive merger, making this governance change a fresh development for shareholders to assess. Globus Medical, trading at $87.35 as of the last close, has seen its share price move 17.5% over the past year and 63.4% over the past 3 years. Recent attention around NYSE:GMED has...
NYSE:PK
NYSE:PKHotel and Resort REITs

A Look At Park Hotels & Resorts (PK) Valuation After Latest Annual Results And Earnings Outlook

Why Park Hotels & Resorts is on investors’ radar Park Hotels & Resorts (PK) has drawn fresh attention after its latest annual figures showed revenue of US$2,545.0 million alongside a net income loss of US$283.0 million, prompting investors to reassess this lodging REIT. See our latest analysis for Park Hotels & Resorts. At a share price of US$10.60, Park Hotels & Resorts has seen short-term pressure, with a 1-month share price return of a 4.5% decline, even though the 3-year total shareholder...
NasdaqGM:TMDX
NasdaqGM:TMDXMedical Equipment

TransMedics Expands OCS Program As Kidney And Lung Platform Story Grows

TransMedics Group expanded its National Organ Care System Program, aiming to handle a larger share of U.S. transplant procedures. The company is advancing kidney and lung transplant initiatives, including full control of the ENHANCE clinical trial. TransMedics is preparing simultaneous U.S. and Europe clinical trial launches for its kidney program as part of a broader transplant platform push. TransMedics Group, NasdaqGM:TMDX, is pushing beyond its medical device roots toward a more...